Tyrosine kinase inhibitorFDA-approvedFirst-line
Vizimpro
Generic name: dacomitinib
How it works
Blocks the activity of multiple proteins involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, patients treated with Vizimpro had a response rate of approximately 44% and a median progression-free survival of around 14 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Treatments for EGFR-Mutated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.